Download PDF
Klin Monbl Augenheilkd 2024; 241(04): 378-380
DOI: 10.1055/a-2215-8576
Der interessante Fall

Protracted Intralenticular Implant of Sustained-Release Dexamethasone Implant (Ozurdex)

Dauerhafte Persistenz des Langzeit-Implantats Ozurdex in der menschlichen Linse
Tim Beltraminelli 
1   Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland
,
Jelena Potic
2   Retina Surgery, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland
,
Theodor Stappler
2   Retina Surgery, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland
,
Thomas J. Wolfensberger
1   Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland
,
Lazaros Konstantinidis
3   Vitreoretinal, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Introduction

The Ozurdex implant was designed to obtain a slow release of dexamethasone over a period of several months for the treatment of macular edema in the context of diabetic retinopathy or retinal vein occlusion, or in the treatment of noninfectious uveitis [1] [2] [3]. The treatment is administered through an intravitreal injection (IVT), and in the vitreous, it releases dexamethasone gradually over time, reducing inflammation and fluid buildup in the macula, thereby improving vision. Complications related to Ozurdex treatment are mostly ascribed to the known side effects of corticosteroid administration to the eye, namely, increased intraocular pressure (IOP), glaucoma, and cataract formation [4]. However, the risks caused by an IVT should be carefully weighted when considering an Ozurdex implant. Indeed, albeit very rare, cases of endophthalmitis have been reported [5]. Here, we present a case of another very rare complication, the inadvertent implantation of the Ozurdex implant into a crystalline lens.



Publication History

Received: 28 October 2023

Accepted: 15 November 2023

Article published online:
23 April 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Haller JA, Bandello F, Belfort jr. R. et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453-2460
    CrossrefPubMedGoogle Scholar
  • 2 Lowder C, Belfort jr. R, Lightman S. et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-553
    CrossrefPubMedGoogle Scholar
  • 3 Boyer DS, Yoon YH, Belfort jr. R. et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904-1914
    CrossrefPubMedGoogle Scholar
  • 4 Gaballa SA, Kompella UB, Elgarhy O. et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res 2021; 11: 866-893
    CrossrefPubMedGoogle Scholar
  • 5 Celik N, Khoramnia R, Auffarth GU. et al. Complications of dexamethasone implants: risk factors, prevention, and clinical management. Int J Ophthalmol 2020; 13: 1612-1620
    CrossrefPubMedGoogle Scholar
  • 6 Schmitz K, Maier M, Clemens CR. et al. [Reliability and safety of intravitreal Ozurdex injections. The ZERO study]. Ophthalmologe 2014; 111: 44-52
    PubMedGoogle Scholar
  • 7 Meyer CH, Rodrigues EB, Michels S. et al. Incidence of damage to the crystalline lens during intravitreal injections. J Ocul Pharmacol Ther 2010; 26: 491-495
    CrossrefPubMedGoogle Scholar
  • 8 Rosenfeld PJ, Brown DM, Heier JS. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431
    CrossrefPubMedGoogle Scholar
  • 9 Chalioulias K, Muqit MM. Vitreoretinal surgery for inadvertent intralenticular Ozurdex implant. Eye (Lond) 2014; 28: 1523-1524
    CrossrefPubMedGoogle Scholar
  • 10 Berarducci A, Sian IS, Ling R. Inadvertent dexamethasone implant injection into the lens body management. Eur J Ophthalmol 2014; 24: 620-622
    CrossrefPubMedGoogle Scholar
  • 11 Clemente-Tomas R, Hernandez-Perez D, Neira-Ibanez P. et al. Intracrystalline Ozurdex®: therapeutic effect maintained for 18 months. Int Ophthalmol 2019; 39: 207-211
    CrossrefPubMedGoogle Scholar
  • 12 Regan KA, Blake CR, Lukowski ZL. et al. Intralenticular Ozurdex® – One Year Later. Case Rep Ophthalmol 2017; 8: 590-594
    CrossrefPubMedGoogle Scholar
  • 13 Poornachandra B, Kumar VBM, Jayadev C. et al. Immortal Ozurdex: A 10-month follow-up of an intralenticular implant. Indian J Ophthalmol 2017; 65: 255-257
    CrossrefPubMedGoogle Scholar
  • 14 Chhabra R, Kopsidas K, Mahmood S. Accidental insertion of dexamethasone implant into the crystalline lens–12 months follow-up. Eye (Lond) 2014; 28: 624-625
    CrossrefPubMedGoogle Scholar
  • 15 Baskan B, Cicek A, Gulhan A. et al. Ozurdex completely located inside a crystallized lens – Results of 14 months. Am J Ophthalmol Case Rep 2016; 4: 38-40
    CrossrefPubMedGoogle Scholar
  • 16 Albuainain A, Al Jindan M, Al Bloushi B. Surgical removal of inadvertent intralenticular sustained-release dexamethasone implant (ozurdex) and implant one-piece posterior capsule intraocular lens. Saudi J Ophthalmol 2020; 34: 145-147
    CrossrefPubMedGoogle Scholar